Keros Therapeutics, Inc. — Cash Flow Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Capital Allocation
How management deploys cash: investing in the business (Capex + M&A) vs returning to shareholders (Buybacks + Dividends).
Capital Allocation Waterfall
Buybacks vs Stock-Based Comp
Cash Flow
Cash Flow by Activity
Earnings Quality (Net Income vs Operating Cash Flow)
Operating Cash Flow
$3M
Free Cash Flow↑+53.6% +$155K
$-134K
Investing Cash Flow↑+40.3% +$381K
$-565K
Financing Cash Flow↓-99.9% -$156M
$140K
Capex↓-53.6% -$155K
$134K
Stock-Based Comp↓-20.6% -$2M
$7M
D&A↑+20.5% +$68K
$400K
SBC Allocated Expense↓-20.6% -$2M
$7M
SBC Unrecognized Cost
—